Trinity Biotech PLC to Discuss Waveform Acquisition and Third Quarter Results-M&A Call Transcript
Greetings, and welcome to the Trinity Biotech corporate update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Eric Ribner. Thank you, Mr. Ribner, you may begin.
Thanks very much, and thank you all for joining us today to review Trinity Biotech's entry into the wearable biosensor market and associated intended partnership with Bayer and its amended credit agreement and strengthened investment relationship with Perceptive Advisors. We will also touch on the company's Q3 2023 results. Joining us on today's call are John Gillard, Chief Executive Officer; and Des Fitzgerald, Chief Financial Officer.
Before we begin, please note that statements made during this conference call may be deemed forward looking within the meaning of federal securities laws. These statements are subject to known and unknown risks and uncertainties that may cause actual events to differ from those expressed or implied in such statements.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |